ARGX vs AZN
argenx SE vs AstraZeneca PLC — AI-powered side-by-side comparison
VS
AZN
AstraZeneca PLC
56
Watch
| Metric | ARGX | AZN |
|---|
| AI Score |
69
|
56
|
| Price |
$864.40
|
$158.74
|
| P/E Ratio |
31.34×
|
23.81×
|
| ROE |
17.6%
|
21.1%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.9%
|
79.3%
|
| Debt / Equity |
0.01×
|
0.64×
|
| Dividend Yield |
0.0%
|
1.3%
|
| RSI (14) |
47.9
|
33.8
|
| Beta |
-0.022
|
0.211
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ARGX versus AZN.
ARGX leads by 13 points.
ARGX scores 69/100 (Buy) versus AZN at 56/100 (Watch).
ARGX Committee View
67% agreement
6 analysts
The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
AZN Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — current ratio of 0.94 is tight -- limited short-term liquidity cushion. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 21.7% shows genuine earnings power backing the valuation — Value
- EPS growing 25.9% YoY — Growth
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 5.9x prices in significant intangible value — Value
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical